medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2012, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2012; 59 (1)

Herpesvirus 8: Kaposi’s sarcoma, Castleman’s disease, and primary effusion lymphoma

Barba EJR

Language: Spanish
References: 121
Page: 43-55
PDF size: 107.32 Kb.


ABSTRACT

From the appearance of the pandemic of the AIDS to ends of last century, the interest for the increase in the incidence of Kaposi´s sarcoma (SK) arose. Diverse studies allowed to discovery the causal agent of this pathology as well as of another two illnesses linfoproliferative not common. At the present time have been able to establish the relationship between these neoplastic illnesses and the infection with the human herpes virus 8 (HHV-8) called also herpes virus associated with SK. Presently work thinks about the main characteristic of the virus as well as of the pathologies before mentioned.


REFERENCES

  1. Dupin N, Fisher C, Kellam P, Ariad S, Tullizer M, Franck N, van Marck E et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi`s sarcoma, multicentric Castleman´s disease, and primary effusion lymphoma. Proc Natl Acad Sci 1999; 96: 4546-4551.

  2. Carbone A, Cesarman E, Spina M, Gioghini A, Schulz T. HIV-associated lymphomas and gamma-herpesviruses. Blood 2009; 113: 1213-1224.

  3. Lynnette T, Jackson O, Patrick K, Wilson B, Stefano P. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agents Cancer 2010; 5: 12-19.

  4. Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Meei-Li Huang, Wald A. Valganciclovir for suppression of human herpesvirus–8 replication: A randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23–30.

  5. Ichikawa S, Otawa M, Teishikata Y, Yamada K, Fujimuro M, Yokosawa H, Matsuda A. 9-(2-C-Cyano-2-deoxy-b-D-arabino-pentofuranosyl)guanine, a potential antitumor agent aginst B-lymphoma infected with Kaposi´s sarcoma-associated herpesvirus. Nucleic Acids Symposium Series 2009; 53: 95-96.

  6. Grzegorz S, Päivi MO. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo. New hope for treating aggressive viral lymphomas. Cell Cycle 2007; 6 (18): 2205-2209.

  7. Schulz TF. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8). J General Virology 1998; 79: 1573–1591.

  8. Sunill M, Reid E, Lechowicz MJ. Update on HHV-8-associated malignancies. Curr Infect Di Rep 2010; 12: 147-154.

  9. Karl-Henning Kalland, Xi-Song Ke, Anne Margrete Oyan. Tumour virology – history, status and future challenges. APMIS 2009; 117: 382–399.

  10. Dagna L, Broccolo F, Paties CT, Ferrarini M, Sarmati L et al. A relapsing inflammatory syndrome and active human herpesvirus 8 infection. N Engl J Med 2005; 353 (2): 156-163.

  11. Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473-3475.

  12. Plancoulaine S, Abel L, Trégouët D, Duprez R, van Beveren M, Torteoye P, Froment A, Gessain A. Respective roles of serological status and blood specific antihuman herpesvirus 8 antibody levels in human herpesvirus 8 intrafamilial transmission in a highly endemic area. Cancer Res 2004; 64: 8782-8787.

  13. Wang OJ, Huang XL, Rappocciolo G, Jenkins FJ, Hildebrand WH, Fan Z, Thomas EZ, Rinaldo CR. Identification of an HLA A*0201-restricted CD8+T-cell epitope for the glycoprotein B homolog of human of human herpesvirus 8. Blood 2002; 99: 3360-3366.

  14. Aoki Y, Yarchoan R, Wyvill K, Shin-Ichiro Okmoto, Little RF, Tosato G. Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood 2001; 97 (7): 2173-2176.

  15. Davis DA, Singer KE, Reynolds IP, Haque M, Yarchoan R. Hypoxia enhances the phosphorylation and cytotoxicity of ganciclovir and zidovudine in Kaposi’s sarcoma-associated herpesvirus–infected cells. Cancer Res 2007; 67 (14): 7003–7010.

  16. Lubyova B, Kellum MJ, Frisancho JA, Pitha PM. Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. J Biol Chem 2007; 282 (44): 31944–31953.

  17. Boulanger E, Meignin V, Oksenhendler E. Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol 141: 557–563.

  18. Marshall V, Parks T, Bagni R, Dian Wang C, Samols MA, Hu J, Wyvil KM, Aleman K, Little RF, Yarchoan R, Renne R, Whitby D. Conservation of virally encoded microRNAs in Kaposi sarcoma–associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. J Infect Dis 2007; 195: 645–59.

  19. Rinat Abada, Tsofia Dreyfuss-Grossman, Yifat Herman-Bachinsky, Haim Geva, Shiri Rivka Masa, Ronit Sarid. SIAH-1 Interacts with the Kaposi’s Sarcoma-Associated Herpesvirus-Encoded ORF45 Protein and Promotes Its Ubiquitylation and Proteasomal Degradation. Journal of Virology, 2008; 82 (5): 2230–2240.

  20. Sang-Hoon Sin, Debasmita Roy, Ling Wang, Michelle R. Staudt, Farnaz D. Fakhari, Dhavalkumar D. Patel, David Henry, William J. Harrington Jr, Blossom A. Damania, Dirk P. Dittmer. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007; 109: 2165-2173.

  21. Ferry JA, Sohani AR, Longtine JA, Schwartz RA, Harris NL. HHV8-positive, EBV-positive Hodgkin lymphoma-like large B-cell lymphoma and HHV8-positive intravascular large B-cell lymphoma. Modern Pathol 2009; 22: 618–626.

  22. Di Bartolo DL, Cannon M, Yi-Fang Liu, Renne R, Chadburn A, Boshoff C, Cesarman E. KSHV LANA inhibits TGF-b signaling through epigenetic silencing of the TGF-b type II receptor. Blood 2008; 111: 4731-4740.

  23. Gregory SM, West JA, Dillon PJ, Hilscher C, Dittmer DP, Damania B. Toll-like receptor signaling controls reactivation of KSHV from latency. PNAS 2009; 106 (28): 11725–11730.

  24. Sarek G, Kurki S, Enbäck J, Iotzova G, Haas J, Laakkonen P, Laiho M, Ojala PM. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007; 117 (4): 1019-1028.

  25. Sarek G, Järviluoma , Moore HM, Tojkander S, Vartia S, Biberfeld P, Laiho M, Ojala PM. Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency. PLoS Pathogens 2010; 6 (3): 1-13.

  26. Tomlinson CC, Damania B. Critical role for endocytosis in the regulation of signaling by the Kaposi’s sarcoma-associated herpesvirus K1 protein. J Virol 2008; 82 (13): 6514–6523.

  27. Yan-Jin Zhang, Bonaparte RS, Patel D, Stein DA, Iversen PL. Blockade of viral interleukin 6 expression of Kaposi’s sarcoma- associated herpesvirus. Mol Cancer Ther 2008; 7 (3): 712–720.

  28. Mesri EA, Cesarman E, Arvanitakis L, Rafii S, Moore MAS et al. Human herpesvirus-8/Kaposi´s sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med 1996; 183: 2385-2390.

  29. Corbellino MB, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473-3475.

  30. Du Ming-Qing, Diss TC, Liu H, Ye H, Hamoudi RA, Cabecadas J, Dong HY, Harris NL, Chan JKC, Rees JW, Dogan A, Isaacson PG. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002; 100: 3415-3418.

  31. Cool CD, Rai PR, Yeager ME, Hernandez-Saavedra D, Serls AE, Bull TM, Geraci MW, Brown KK, Routes JM, Tuder RM, Voelkel NF. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113-1122.

  32. Durrington HJ, Upton PD, Hoer S, Boname J, Dunmore BJ, Yang J, Crilley TK, Butler LM, Blackbourn DJ, Nash GB, Lehner PJ, Morrell NW. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem 2010; 285 (48): 37641-37649.

  33. Subramanian R, D’Auvergne O, Kong H, Kousoulas KG. The cytoplasmic terminus of Kaposi’s sarcoma-associated herpesvirus glycoprotein B is not essential for virion egress and infectivity. J Virol 2008; 82 (14): 7144–7154.

  34. Grzegorz S, Päivi MO. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo. New hope for treating aggressive viral lymphomas. Cell Cycle 6: 18, 2205-2209.

  35. Judde JG, Lacoste V, Brie`re J, Kassa-Kelembho E, Clyti E, Couppie´ P, Buchrieser C, Tulliez M, Morvan J, Gessain A. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi’s sarcoma and other diseases. J Natl Cancer Inst 2000; 92: 729–736.

  36. Schulz TF. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus-8). J Gen Virol 1998; 79: 1573–1591.

  37. Tisdale JF, Stewart AK, Dickstein B, Little RF, Dube I, Cappe D, Dunbar CE, Brown KE. Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: ORF 26 sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. Blood 1998; 92 (8): 2681-2687.

  38. Kishimoto Tadamitsu. IL-6: From its discovery to clinical applications. Internat Immunol 2010; 22 (5): 347-352.

  39. Hong L, Nicholas J. Identification of amino acid residues of gp130 signal transducer and gp80 a receptor subunit that are involved in ligand binding and signaling by human herpesvirus 8-encoded interleukina-6. J Virol 2002; 76 (11): 5627-5636.

  40. Gómez Román JJ, Ocejo VG, Sánchez VP, Hernández NE, Leyva CF, Val Bernal JF. Presence of human herpesvirus-8 DNA sequences and overexpression of human IL-6 and cyclin D1 in inflammatory myofibroblastic tumor (inflammatory pseudotumor). Lab Invest 2000; 80: 1121-1126.

  41. Ye J, Gradoville L, Daigle D, Miller G. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi’s sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists. J Virol 2007; 81 (17): 9279–9291.

  42. González CM, Wang L, Damania B. Kaposi’s sarcoma-associated herpesvirus encodes a viral deubiquitinase. J Virol 2009; 83 (19): 10224-10233.

  43. Petre CE, Sang-Hoon Sin, Dittmer DP. Functional p53 signaling in Kaposi’s sarcoma-associated herpesvirus lymphomas: Implications for therapy. J Virol 2007; 81 (400): 1912–1922

  44. Cloutier N, Flamand L. Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon beta (IFN-b) expression by competing with IFN regulatory factor-3 for binding to IFN-b promoter. www.jbc.org by guest, on June 11, 2011.

  45. Günther T, Grundhof A. The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes. PLoS Pathogens 2010; 6 (6): 2-19.

  46. Punjabi AS, Carroll PA, Chen L, Lagunoff M. Persistent activation of STAT3 by latent Kaposi’s sarcoma-associated herpesvirus infection of endothelial cells. J Virol 2007; 81 (5): 2449–2458.

  47. Wies E, Mori Y, Hahn A, Kremmer E, Stürzl M, Fleckenstein B, Neipel F. The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 2008; 111: 320-327.

  48. Dyson OF, Oxendine TL, Hamden KE, Ford PW, Akula SM. Differential regulation of the attachment of KSHV infected human B cells to ECM by KSHV encoded gB and cellular aV integrins. Cell Microbiol 2008; 10 (7): 1546–1558.

  49. Dalton-Griffin L, Wilson SJ, Kellam P. X-box binding protein 1 contributes to induction of the Kaposi’s sarcoma-associated herpesvirus lytic cycle under hypoxic conditions. J Virol 2009; 83 (14): 7202–7209.

  50. Marcos-Villar L, Lopitz-Otsoa F, Gallego P, Muñoz-Fontela C, González SJ, Campagna M, Shou-Jiang G, Rodríguez MS, Rivas C. Kaposi’s sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J Virol 2009; 83 (17): 8849–8858.

  51. Sarid R, Klepfish A, Schattner A. Virology, pathogenetic mechanisms, and associated diseases of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8). Mayo Clin Proc 2002; 77: 941-949.

  52. Lepone L, Rappocciolo G, Knowlton E, Jais M, Piazza P, Jenkins FJ, Rinaldo CR. Monofunctional and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins. Clin Vaccine Immunol 2010; 17 (10): 1507–1516.

  53. Plancoulaine S, Gessain A, van Beveren M, Tortevoye P, Abel L. Evidence for a recessive major gene predisposing to human herpesvirus 8 (HHV-8) infection in a population in which HHV-8 is endemic. JID 2003; 187: 1944-1950.

  54. Sam M. Mbulaiteye, Ruth M. Pfeiffer, Denise Whitby, Glen R. Brubker, John Shao, Robert J. Biggar. Human Herpesvirus 8 Infection within Families in Rural Tanzania. JID 2003; 187: 1780-1785.

  55. Xing W, Bin H, Zhaoxia Z, Tao L, Hui W, Xu L, Qiong Z, Ke L, Xiaomei L, Hao W. Human herpesvirus-8 in northwestern China: epidemiology and characterization among blood donors. Virol J 2010; 7: 62-68.

  56. Greenblatt R, Jacobson L, Levine A, Cohen M, DeHovitz J, Young M, Burns D, Miotti P, Koelle D. Human herpesvirus 8 infection and Kaposi´s sarcoma among human immunodeficiency virus-infected and –uninfeceted women. J Infect Dis 2001; 183: 1130-1134.

  57. Pellett PE, Spira TJ, Bagasra O, Boshoff C, Corey L, de Lellis L, Huang ML, Lin JC, Matthews S, Monini P, Rimessi P, Sosa C, Wood C, Stewart LA. Multicenter comparison of PCR assays for detection of human herpesvirus 8 DNA in semen. J Clin Microbiol 1999; 37 (5): 1298-1301.

  58. Gambús G, Bourboulia D, Esteve A, Lahoz R, Rodriguez C, Bolao F, Sirera G, Muga R, del Romero J, Boshoff C, Whitby D, Casabona J. Prevalence and distribution of HHV-8 in different subpopulations, with and without HIV infection, in Spain. AIDS 2001; 15: 1167-1174.

  59. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007; 12: 569-576.

  60. Queiroga EM, Gualco G, Chioato L et al. Viral studies in Burkitt Lymphoma. Association With Epstein-Barr virus but not HHV-8. Am J Clin Pathol 2008; 130: 186-192.

  61. Mark R. Howard, Denise Whitby,Gulam Bahadur, Fiona Suggett, Chris Boshoff, Melinda Tenant-Flowers, Thomas F. Schulz, Stuart Kirk, Steve Matthews, Ian V.D. Weller, Richard S. Tedder, Robin A. Weiss. Detection of human herpesvirus 8 DNA in semen from HIV-infected individuals but not healthy semen donors. AIDS 1997: 11: F15–F19.

  62. Melbey M, Cook PM, Hjalgrim H, Begtrup K, Simpson GR, Biggar RJ, Ebbesen P, Schulz TF. Risk factors for Kaposi´s-sarcoma-associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981–1996. Int J Cancer 1998; 77: 543–548.

  63. Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G, Cohn S, Whitby D, Goedert JJ. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 2007; 196: 199–207.

  64. Mancuso R, Biffi R, Valli M, Bellinvia M, Athanasia T, Ferrucci S, Brambilla L, Delbue S, Ferrante P, Tinelli C, Clerici M. HHV-8 A subtype is associated with rapidly evolving classic Kaposi’s sarcoma. J Med Virol 2008; 80 (12): 2153–2160.

  65. Zong JC, Kajumbula H, Boto W, Hayward GS. Evaluation of global clustering patterns and strain variation over an extended ORF26 gene locus from Kaposi’s sarcoma herpesvirus. J Clin Virol 2007; 40 (1): 19–25.

  66. Tedeschi R, De Paoli P, Schulz TF, Dillner J. Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. J Infect Dis 1999; 179: 1016–1020.

  67. Rabkin CS, Schulz TF, Whitby D, Lennette ET, Magpantay LI, Chatlynne L, Biggar RJ. Interassay correlation of human herpesvirus 8 serologic tests. J Infect Dis 1998; 178: 304–309.

  68. Renwick N, Halaby T, Weverling GJ, Dukers NHTM, Simpson GR, Coutinho RA, Lange JMA, Schulz TF, Goudsmit J. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi’s sarcoma. AIDS 1998; 12: 2481–2488.

  69. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. Epidemiology, pathophysiology, and treatment of Kaposi sarcoma–associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008; 47: 1209–1215.

  70. Ling W, Blossom D. Kaposi’s sarcoma–associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 2008; 68 (12): 139-143.

  71. Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci USA 1996; 93: 6641-6646.

  72. Davis MA, Stürzl M, Blasing C, Schereier A, Guo HG, Reitz M, Opalenik SR, Browning PJ. Expression of human herpesvirus 8-encoded cyclin D in Kaposi´s sarcoma spindle cells. J Natl Cancer Inst 1997; 89: 1968-1974.

  73. Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH, Tschachler E, Colombini S, Ensoli B, Stürzl M. Monocytes in Kaposi´s sarcoma lesions are productively infected by human herpesvirus 8. J Virol 1997; 71 (10): 7963-7968.

  74. Du MQ, Liu H, Diss TC, Ye H, Hamoudi RA, Dupin N, Meignin V, Oksenhendler E, Boshoff C, Isaacson PG. Kaposi sarcoma-associated herpesvirus infects monotypic (IgMl)but polyclonal naïve B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001; 97:2130-2136.

  75. Toby M, Ponte M, Leslie K. HIV-associated Kaposi´s sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357 (13): 1352-1353.

  76. Martró E, Esteve A, Schulz TF, Sheldon J, Gambús G, Muñoz R, Whitby D, Casabona J. Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi’s sarcoma among men who have sex with men in a European multicentre study. Int J Cancer 2006; 120: 1129–1135.

  77. Plancoulaine S, Abel L, van Beveren M, Gessain A. High titers of anti-human herpesvirus 8 antibodies in elderly males in an endemic population. J Natl Cancer Inst 2002; 94: 1333-1335.

  78. Skalsky RL, Samols MA, Plaisance KB, Boss IW, Riva A, Lopez MC, Baker HV, Renne R. Kaposi’s sarcoma-associated herpesvirus encodes an ortholog of miR-155. J Virol 2007; 81 (23): 12836–12845.

  79. de Vries IAC, van Acht MMS, Demeyer TBJ, Lybeert MLM, de Zoete JP, Niuwenhuijzen GAP. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman´s disease: A case report and review of the literature. Radiation Oncology 2010; 5 (7): 1-6.

  80. Casper C. The etiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2004; 129: 3-17.

  81. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d’Agay MFG, Clauvel JP, Raphael M, Degos L, Sigaux FG. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995; 86 (4): 1276-1280.

  82. Montani D, Achouch L, Marcelin AG, Viard JP, Hermine O, Canioni O, Sitbon O, Simonneau G, Humbert M. Case study. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman´s disease. Eur Respir J 2005; 26: 969-972.

  83. Corey C, Nichols WG, Huang L, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103: 1632-1634.

  84. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicéntrica Castleman disease in HIV-infected patients. Blood 2000; 96: 2069-2073.

  85. Guihot A, Couderc L-J, Agbalika F, Galicier L, Bossi P, Rivaud E, Scherrer A, Zucman D, Katlama C, Oksenhendler E. Pulmonary manifestations of multicéntrica Castleman´s disease in HIV infection: A clinical, biological and radiological study. Eur Respir J 2005; 26: 118-125.

  86. Montani D, Achouh L, Marcelin AG, Viard JP, Hermine O, Canioni D, Sitbon O, Simonneau G, Humbert M. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman´s disease. Eur Respir J 2005; 26: 969-972.

  87. Hassman LM, Ellison TJ, Kedes DH. KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation. J Clin Invest 2011; 121 (2): 752-768.

  88. McClain K, Natkunam Y, Swerdlow S. Atypical cellular disorders. Hematology 2004; 283-296.

  89. Fadi B, Rene´ PM, Karim K, Manon A. Primary effusion lymphoma. A series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007; 111: 224–233.

  90. Niino D, Tsukasaki K, Torii K, Imanishi D, Tsuchiya T, Onimaru Y, Tsushima H, Yoshida S, Yamada Y, Kamihira S, Tomonaga M. Human herpes virus 8-negative primary effusion lymphoma with BCL6 rearrangement in a patient with idiopathic CD4 positive T-lymphocytopenia. Haematologica 2008; 93: e21-e22.

  91. Calabro ML, Gasperini P, Di Gangi IM, Indraccolo S, Barbierato M, Amadori A, Chieco-Bianchi L. Antineoplastic activity of lentiviral vectors expressing interferon-a in a preclinical model of primary effusion lymphoma. Blood 2009; 113: 4525-4533.

  92. O’Hara AJ, Wang L, Dezube BJ, Harrington WJ Jr, Damania B, Dittmer DP. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 2009; 113: 5938-5941.

  93. Boulanger E, Hermine O, Fermand JP, Radford-Weiss I, Brousse N, Meignin V, Gessain A. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-Negative Elderly Patients. Am J Hematol 2004; 76:88-91.

  94. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Okenhendler E. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-4380.

  95. Hocqueloux L, Agbalika F, Okesenhendler E, Molina JM. Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 2001; 15(2): 280-282.

  96. Ikebe T, Amemiya Y, Saburi M, Ando T, Kohno K, Ogata M, Hiramatsu K, Kadota J. Rare primary effusion lymphoma associated with HHV-8 in Japan. Inter Med 2010; 49: 1303-1306.

  97. Terasaki Y, Okumura H, Saito K, Sato Y, Yoshino T, Ichinohasama R, Ishida Y. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleura drainage followed by chemotherapy containing rituximab. Inter Med 2008; 47: 2175-2178.

  98. Wang HY, Fuda FS, Chen W, Karandikar NJ. Notch1 in primary effusion lymphoma: a clinicopathological study. Modern Pathology 2010; 23: 773–780.

  99. Meloa NCV, Salesb MM, Santanab ANC, Costalongaa EC, Pedreiraa AB, Ianheza LE. Pleural Primary Effusion Lymphoma in a Renal Transplant Recipient. American Journal of Transplantation 2008; 8: 906–907.

  100. Harbell JW, Dunn TB, Fauda M, John DG, Goldenberg AS, Tepermana LW. Transmission of anaplastic large cell lymphoma via organ donation after cardiac death. Am J Transplant 2008; 8: 238–244.

  101. Hussain AR, Al-Jomah NA, Siraj AK, Manogaran P, AlHussein K, Abubaker J, Platanias LC, Al-Kuraya KS, Uddin S. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007; 67 (8): 3888–3897.

  102. Rimessi P, Bonaccorsi A, Stürzi M, Fabris M, Brocca-Cofano E, Caputo A, Melucci-Vigo G, Falchi M, Cafaro A, Cassai E, Ensoli B, Monini P. Transcription pattern of human herpesvirus 8 pen reading frame K3 in primary effusion lymphoma and Kaposi sarcoma. J Virol 2001; 75 (15): 7161-7174.

  103. Nun TK, Kroll DJ, Oberlies NH, Soejarto DD, Case RJ, Piskaut P, Matainaho T, Hilscher C, Wang L, Dittmer DP, Gao SJ, Damania B. Development of a fluorescence-based assay to screen antiviral drugs against Kaposi’s sarcoma–associated herpesvirus. Mol Cancer Ther 2007; 6 (8): 2360–2370.

  104. Boulanger E, Meignin V, Afonso PV, Duprez R, Oksenhendler E, Agbalika F, Gessain A. Extracavitary tumor after primary effusion lymphoma: Relapse or second distinct lymphoma? Haematologica 2007; 92: 1275-1276.

  105. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, Vaccher E, Carbone A, Tirelli U. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study. J Clin Oncol 2003; 21: 3948-3954.

  106. Chen D, Sandford G, Nicholas J. Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. J Virol 2009; 83 (2): 722–733.

  107. O’Hara AJ, Vahrson W, Dittmer DP. Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood 2008; 111: 2347-2353.

  108. Chen D, Choi YB, Sandford G, Nicholas J. Determinants of secretion and intracellular localization of human herpesvirus 8 interleukin-6. J Virol 2009; 83 (13): 6874–6882.

  109. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, Zhao L, Trivedi P, Jones C, Zhang L. Epstein-Barr virus inhibits Kaposi’s sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol 2007; 81 (11): 6068–6078.

  110. Rhodes DA, Boyle LH, Boname JM, Lehner PJ, Trowsdale J. Ubiquitination of lysine-331 by Kaposi’s sarcoma associated herpesvirus protein K5 targets HFE for lysosomal degradation. PNAS 2010; 107 (37): 16240–16245.

  111. Wilson SJ, Tsao EH, Webb BLJ, Ye H, Dalton-Griffin L, Tsantoulas C, Gale CV, Du MQ, Whitehouse A, Kellam P. X Box binding protein XBP-1s transactivates the Kaposi’s sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. J Virol 2007; 81 (24): 13578–13586.

  112. Boulanger E, Marchio A, Hong SS, Pineau P. Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1/b-catenin genes in human herpesvirus 8-associated primary effusion lymphoma. Haematologica 2009; 94 (8): 1170-1174.

  113. Liu J, Martin H, Shamay M, Woodard C, Tang QQ, Hayward SD. Kaposi’s sarcoma-associated herpesvirus LANA protein downregulates nuclear glycogen synthase kinase 3 activity and consequently blocks differentiation. J Virol 2007; 81 (9): 4722–4731.

  114. Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, Herrington CS, Moore PS, Schulz TF. The 222- to 234 kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 1997; 71 (8): 5915-5921.

  115. Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud E, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M, Boue F, Galanaud P. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms. Blood 1994; 84 (8): 2472-2479.

  116. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E. Prognostic factors and outcome of human herpesvirus 8–associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-4380.

  117. Grossman Z, Iscovich J, Schwartz F, Azizi E, Klepfish A, Schattner A, Sarid R. Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc 2002; 77: 905-909.

  118. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 2006; 107: 3832-3840.

  119. Nun TK, Kroll DJ, Oberlies NH, Soejarto DD, Case RJ, Piskaut P, Matainaho T, Hilscher C, Wang L, Dittmer DP, Gao SJ, Damania B. Development of a fluorescence-based assay to screen antiviral drugs against Kaposi’s sarcoma– associated herpesvirus. Mol Cancer Ther 2007;6(8):2360–2370.

  120. Du MQ, Diss TM, Liu H, Ye H, Hamoudi RA, Cabecadas J, Dong HY, Harris NL, Chan JKC, Rees JW, Dogan A, Isaacson PG. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002; 100: 3415-3418.

  121. Durrington HJ, Upton PD, Hoer S, Boname J, Dunmore BJ, Yang J, Crilley TK, Butler LM, Blackbourn DJ, Nash GB, Lehner PJ, Morrell NW. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem 2010; 285 (48): 37641–37649.




2020     |     www.medigraphic.com